Anti diabetic drugs corticosteroids contraceptives drugs for osteoporosis classification and mechanism of action according to kdt in a tabulation form

Reading File

Finding Sources

KDT is not in the library. I'll answer directly from my comprehensive knowledge of KD Tripathi's pharmacology. Here is the detailed tabulation as per KDT:

Pharmacology Tables as per KD Tripathi (KDT) - Essentials of Medical Pharmacology

1. ANTIDIABETIC DRUGS

A. Insulin Preparations

Class	Drug Examples	Mechanism of Action
Rapid-acting	Regular (soluble) insulin, Insulin lispro, Aspart, Glulisine	Binds insulin receptor (tyrosine kinase) → GLUT4 translocation → glucose uptake in muscle & fat; inhibits glycogenolysis & gluconeogenesis
Intermediate-acting	NPH (Isophane) insulin, Insulin lente	Same as above; delayed onset due to protamine/zinc suspension
Long-acting	Insulin glargine, Detemir, Degludec	Same receptor mechanism; prolonged action due to altered isoelectric point (glargine) or fatty acid binding (detemir/degludec)
Premixed	30/70 (NPH + Regular), Biphasic aspart	Combination of above mechanisms

B. Oral Antidiabetic Drugs (OADs)

Class	Drug Examples	Mechanism of Action
Sulphonylureas (1st gen)	Tolbutamide, Chlorpropamide	Block ATP-sensitive K⁺ channels on beta cell membrane → depolarization → Ca²⁺ influx → insulin secretion (insulin secretagogues)
Sulphonylureas (2nd gen)	Glibenclamide (Glyburide), Glipizide, Gliclazide, Glimepiride	Same as above; more potent, fewer side effects; extrapancreatic effects also
Biguanides	Metformin	Activates AMP-kinase → inhibits hepatic gluconeogenesis (main effect); enhances peripheral glucose utilization; does NOT cause hypoglycemia; insulin-sensitizer
Thiazolidinediones (Glitazones)	Pioglitazone, Rosiglitazone	Activate PPAR-γ (nuclear receptor) → increase GLUT1 & GLUT4 expression → insulin sensitization in adipose, muscle, liver
Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose	Inhibit intestinal alpha-glucosidase enzymes → delay carbohydrate digestion & absorption → reduce postprandial hyperglycemia
Meglitinides (Glinides)	Repaglinide, Nateglinide	Bind different site on K⁺ ATP channel → stimulate insulin secretion; rapid & short-acting; postprandial glucose lowering
DPP-4 inhibitors (Gliptins)	Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Linagliptin	Inhibit DPP-4 enzyme → prevent degradation of GLP-1 & GIP → enhanced glucose-dependent insulin secretion; reduce glucagon
GLP-1 receptor agonists	Exenatide, Liraglutide, Dulaglutide, Semaglutide	Mimic GLP-1 → stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, reduce appetite
SGLT-2 inhibitors (Gliflozins)	Dapagliflozin, Empagliflozin, Canagliflozin	Inhibit SGLT-2 in proximal renal tubule → block glucose reabsorption → glucosuria → lower blood glucose (insulin-independent)
Amylin analogue	Pramlintide	Mimics amylin → suppresses postprandial glucagon, slows gastric emptying, reduces food intake

2. CORTICOSTEROIDS

Classification

Class	Natural	Synthetic
Glucocorticoids	Hydrocortisone (cortisol), Cortisone	Prednisolone, Prednisone, Methylprednisolone, Triamcinolone, Dexamethasone, Betamethasone, Budesonide, Fluticasone, Beclomethasone
Mineralocorticoids	Aldosterone, Deoxycorticosterone (DOC)	Fludrocortisone

Based on Duration of Action

Category	Drugs	Equivalent Anti-inflammatory Dose	Half-life
Short-acting	Hydrocortisone, Cortisone	20 mg, 25 mg	8-12 hrs
Intermediate-acting	Prednisolone, Prednisone, Methylprednisolone, Triamcinolone	5 mg, 5 mg, 4 mg, 4 mg	12-36 hrs
Long-acting	Dexamethasone, Betamethasone	0.75 mg, 0.6 mg	36-54 hrs

Mechanism of Action

Step	Action
Receptor binding	Diffuse into cell → bind cytoplasmic glucocorticoid receptor (GR)
Translocation	GR-steroid complex translocates to nucleus
Genomic effects	Binds GRE (glucocorticoid response elements) → regulates gene transcription (trans-activation & trans-repression)
Anti-inflammatory	Induce lipocortin (annexin-1) → inhibit phospholipase A₂ → decrease prostaglandins, leukotrienes, PAF; inhibit COX-2, IL-1, IL-2, IL-6, TNF-α; reduce capillary permeability; inhibit leukocyte migration
Immunosuppressive	Reduce lymphocyte proliferation; induce lymphocyte apoptosis; suppress cell-mediated immunity more than humoral
Metabolic	Gluconeogenesis ↑; protein catabolism ↑; fat redistribution (central obesity); Na⁺ retention, K⁺ loss
Non-genomic	Rapid effects (seconds-minutes) via membrane receptors and second messengers

3. CONTRACEPTIVE DRUGS (Hormonal Contraceptives)

Classification as per KDT

Category	Class	Drug Examples	Mechanism of Action
Combined Oral Contraceptives (COC)	Monophasic	Ethinyl estradiol + Levonorgestrel; EE + Norethindrone; EE + Desogestrel; EE + Drospirenone	Primary: Inhibit midcycle LH surge → suppress ovulation; Secondary: Thicken cervical mucus (sperm penetration ↓); alter endometrium (implantation ↓); alter tubal motility
Combined OC	Biphasic / Triphasic	EE + Norethindrone (varying doses across cycle)	Same as above; attempt to mimic normal cycle
Progestin-only Pills (Mini-pill)	-	Norethindrone, Levonorgestrel, Desogestrel	Thicken cervical mucus (main effect); alter endometrium; may suppress ovulation inconsistently
Injectable Contraceptives	Long-acting progestin	DMPA (Depot medroxyprogesterone acetate) - 150 mg/3 months; Norethindrone enanthate - 200 mg/2 months	Suppress ovulation; cervical mucus thickening; endometrial atrophy
Combined Injectable	Monthly	Medroxyprogesterone + Estradiol cypionate	Suppress ovulation
Implants	Subdermal progestin	Etonogestrel implant (Implanon); Levonorgestrel implant (Norplant)	Continuous progestin → suppress ovulation + cervical mucus effect
Intrauterine devices (Hormonal)	Levonorgestrel IUD	LNG-IUS (Mirena)	Local progestin → endometrial suppression, cervical mucus thickening; minimal systemic effect
Emergency Contraceptives (Post-coital)	High-dose progestin	Levonorgestrel 1.5 mg single dose (within 72 hrs)	Inhibit/delay ovulation; may alter endometrium; does NOT interrupt established pregnancy
Emergency Contraceptives	Antiprogestin	Mifepristone (RU-486) 10 mg	Progesterone receptor antagonist → endometrial changes, inhibit implantation; delays ovulation
Emergency Contraceptives	Selective progesterone receptor modulator	Ulipristal acetate 30 mg (within 120 hrs)	Modulates progesterone receptor → delays/inhibits ovulation
Centchroman (Non-hormonal OC)	SERM	Centchroman (Ormeloxifene)	Selective estrogen receptor modulator → asynchrony between ovulation and endometrial maturation → anti-implantation

4. DRUGS FOR OSTEOPOROSIS

Classification as per KDT

Class	Drugs	Mechanism of Action
Bisphosphonates	Alendronate, Risedronate, Ibandronate, Zoledronate (IV), Etidronate, Clodronate	Adsorb onto hydroxyapatite in bone; taken up by osteoclasts → inhibit farnesyl pyrophosphate synthase (mevalonate pathway) → impair osteoclast function & survival (apoptosis) → reduce bone resorption
Selective Estrogen Receptor Modulators (SERMs)	Raloxifene, Bazedoxifene	Estrogen agonist in bone → inhibit osteoclast activity; estrogen antagonist in breast & uterus → reduce fracture risk without uterine/breast stimulation
Calcium + Vitamin D	Calcium carbonate, Calcium citrate + Cholecalciferol (Vit D3), Calcitriol	Calcium: substrate for bone mineralization; Vit D: increases intestinal Ca²⁺ absorption, renal Ca²⁺ reabsorption, osteoblast function
Hormone Replacement Therapy (HRT)	Conjugated estrogens, Estradiol (±progestogen)	Estrogen → inhibit osteoclast differentiation & activity (via OPG/RANK-L pathway) → reduce bone resorption; also inhibit PTH-mediated bone resorption
Calcitonin	Salmon calcitonin (intranasal/injectable)	Binds calcitonin receptor on osteoclasts → inhibits osteoclast activity directly → reduces bone resorption; also analgesic effect
PTH analogues (Anabolics)	Teriparatide (PTH 1-34), Abaloparatide	Intermittent PTH stimulates osteoblasts more than osteoclasts → net anabolic bone formation (↑ bone mass); only true bone-forming agents
RANK-L inhibitor (Biological)	Denosumab	Monoclonal antibody against RANK-L → prevents RANK-L from binding RANK on osteoclast precursors → inhibits osteoclast formation, function & survival → reduce bone resorption
Strontium ranelate	Strontium ranelate	Dual mechanism: stimulates osteoblast proliferation (bone formation ↑) + inhibits osteoclast differentiation (bone resorption ↓); also incorporates into bone mineral
Romosozumab	Romosozumab	Anti-sclerostin monoclonal antibody → removes sclerostin's inhibition of Wnt signaling → osteoblast activity ↑ (anabolic) + some anti-resorptive effect
Active Vitamin D analogues	Calcitriol, Alfacalcidol	Directly active forms → increase Ca²⁺ absorption; enhance bone mineralization; useful in renal osteodystrophy
Thiazide diuretics	Hydrochlorothiazide	Reduce urinary Ca²⁺ excretion → positive calcium balance → adjunct in osteoporosis

Summary Quick Reference

Drug Group	Primary Target	Net Effect
Bisphosphonates	Osteoclast (farnesyl PP synthase)	Anti-resorptive
Denosumab	RANK-L	Anti-resorptive
Raloxifene	Estrogen receptor (bone agonist)	Anti-resorptive
Calcitonin	Calcitonin receptor on osteoclast	Anti-resorptive
Teriparatide	PTH receptor (osteoblast)	Anabolic
Romosozumab	Sclerostin (Wnt pathway)	Anabolic + anti-resorptive
Strontium ranelate	Osteoblast + osteoclast	Dual action

Note: KD Tripathi's Essentials of Medical Pharmacology (8th edition) is the reference basis for all classifications and mechanisms above. KDT is not in the digital library available here, so this answer is compiled from comprehensive KDT knowledge. For exact page references, consult KDT 8th edition chapters: 19 (Insulin & Antidiabetics), 20 (Adrenocorticoids), 22 (Contraceptives), and 24 (Drugs affecting calcium & bone metabolism).

Give me the mechanism of action of glucocorticoids and mineralocorticoids separately

Finding Sources

Reading File

Loading Image

Both diagrams are perfect. Here is the complete, detailed answer:

Mechanism of Action of Corticosteroids

I. GLUCOCORTICOIDS

(Hydrocortisone, Prednisolone, Dexamethasone, Betamethasone, etc.)

Glucocorticoids act through two major pathways: genomic (slow, dominant) and non-genomic (fast).

A. Genomic Mechanism (Primary)

Step-by-Step Sequence:

Step	Event	Details
1. Entry	Drug diffuses into cell	Being lipophilic, glucocorticoid freely crosses the cell membrane into the cytoplasm
2. Receptor binding	Binds cytosolic Glucocorticoid Receptor (GR)	GR is normally held inactive, complexed with heat shock proteins (HSP-90, HSP-70)
3. HSP dissociation	Drug-GR complex forms; HSPs dissociate	Conformational change exposes nuclear localization signal
4. Dimerization	Two GR-drug complexes dimerize	Forms a homodimer
5. Nuclear translocation	Complex moves to nucleus	Via nuclear pore
6a. Transactivation	Binds GRE (Glucocorticoid Response Elements) on DNA	Activates transcription of anti-inflammatory proteins: lipocortin-1 (annexin-1), IL-10, IκB; also activates genes responsible for metabolic side effects
6b. Transrepression	GR-drug monomer interacts with transcription factors AP-1 & NF-κB	Inhibits transcription of pro-inflammatory genes (COX-2, IL-1, IL-2, IL-6, IL-8, TNF-α) - this is the main anti-inflammatory mechanism

GR transactivation and transrepression diagram from Harrison's Principles of Internal Medicine

Figure: GR transrepression (left) - GR + AP-1 suppress proinflammatory gene transcription; GR transactivation (right) - GR dimer binds GRE to activate anti-inflammatory gene transcription. Source: Harrison's Principles of Internal Medicine, 22e

B. Non-Genomic Mechanism (Rapid)

Mechanism	Effect
Membrane-bound glucocorticoid receptors	Rapid signaling within seconds to minutes
Direct physicochemical interaction with cell membranes	Stabilize lysosomal membranes
Inhibit second messenger systems	Rapid anti-inflammatory effects that precede gene transcription

These rapid (non-genomic) effects occur within seconds to minutes, before any gene transcription can take place.

C. Consequences of Genomic Actions (Pharmacological Effects)

Effect	Mechanism
Anti-inflammatory	Induce lipocortin-1 → inhibit phospholipase A₂ → block arachidonic acid release → reduce prostaglandins, leukotrienes, thromboxanes, PAF; also inhibit COX-2 (via NF-κB suppression)
Immunosuppressive	Suppress IL-2 → reduce T-lymphocyte proliferation; induce lymphocyte apoptosis; suppress cell-mediated > humoral immunity
Anti-allergic	Reduce mast cell degranulation and histamine release
Anti-oedema	Reduce vascular permeability; inhibit vasodilatory mediators
Metabolic (side effects - transactivation)	Gluconeogenesis ↑ (hepatic); protein catabolism in muscle/connective tissue; lipolysis with fat redistribution (central obesity, buffalo hump, moon face)
Na⁺ retention / K⁺ loss	Weak mineralocorticoid effect (especially hydrocortisone, cortisone)
Suppress HPA axis	Negative feedback on hypothalamus (↓ CRH) and pituitary (↓ ACTH)

II. MINERALOCORTICOIDS

(Aldosterone [natural], Fludrocortisone [synthetic], Desoxycorticosterone)

The mechanism is also genomic, but acting on a different receptor (MR) and different target proteins in renal tubular epithelial cells.

Step-by-Step Sequence:

Step	Event	Details
1. Entry	Lipid-soluble aldosterone diffuses through cell membrane into tubular cell cytoplasm	Target cells: principal cells of distal convoluted tubule, connecting tubule & collecting duct
2. Receptor binding	Binds cytoplasmic Mineralocorticoid Receptor (MR)	MR is highly specific for aldosterone; cortisol is inactivated to cortisone by 11β-HSD2 in these cells, preventing cortisol from occupying MR (despite equal affinity); spironolactone competitively blocks MR
3. Nuclear translocation	Aldosterone-MR complex (or a product of it) moves into nucleus	Undergoes further activation
4. Gene transcription	Binds MRE (mineralocorticoid response elements) on DNA → mRNA synthesis	Latency ~30 min before mRNA appears
5. Protein synthesis	mRNA translated into specific transport proteins and enzymes	Begins ~45 min; maximal effect after several hours
6. Transport proteins induced	(a) ENaC (epithelial Na⁺ channel) - inserted in luminal membrane → Na⁺ entry ↑; (b) ROMK (K⁺ channel) in luminal membrane → K⁺ secretion ↑; (c) Na⁺/K⁺-ATPase on basolateral membrane → Na⁺ pumped out → K⁺ taken in; (d) Mitochondrial enzymes → ATP production for active transport	Net effect: Na⁺ (and water) retained; K⁺ and H⁺ excreted

Aldosterone mechanism of action in principal cells of renal tubule from Guyton & Hall

Figure: Aldosterone binds MR → mRNA → ENaC (luminal Na⁺ entry), ROMK (K⁺ secretion), Na⁺/K⁺-ATPase (basolateral pump). Spironolactone blocks MR; Amiloride blocks ENaC. Source: Guyton & Hall Textbook of Medical Physiology

Non-Genomic Actions of Mineralocorticoids

Feature	Details
Rapid effects	Occur within seconds to minutes (too fast for gene transcription)
Mechanism	Membrane-bound receptors, second messenger systems
Significance	Rapid cardiovascular and renal effects, though less well characterized

III. COMPARISON TABLE: Glucocorticoids vs Mineralocorticoids

Feature	Glucocorticoids	Mineralocorticoids
Receptor	Glucocorticoid Receptor (GR / NR3C1)	Mineralocorticoid Receptor (MR / NR3C2)
Receptor location	Cytoplasm (most cells)	Cytoplasm (principal cells, cardiac, vascular)
Primary target organ	Widespread - immune cells, liver, muscle, adipose	Kidney (DCT, collecting duct), colon, salivary glands
Main genomic action	Transactivation (lipocortin, IL-10) + Transrepression (NF-κB, AP-1)	Upregulate ENaC, Na⁺/K⁺-ATPase, ROMK
Net renal effect	Minor Na⁺ retention (some drugs)	Na⁺ & water retention; K⁺ & H⁺ excretion
Anti-inflammatory	Yes (primary action)	No
Onset of genomic effects	Hours (gene transcription)	45 min - hours
Protector from cortisol excess	11β-HSD1 activates cortisol in target tissue	11β-HSD2 inactivates cortisol → prevents MR occupation by cortisol
Blocker (antagonist drug)	Mifepristone (RU-486)	Spironolactone, Eplerenone
Channel blocker (downstream)	-	Amiloride (blocks ENaC)
Key side effects	Hyperglycemia, osteoporosis, myopathy, immunosuppression, HPA suppression	Hypertension, hypokalemia, metabolic alkalosis, oedema

Sources: Guyton & Hall Textbook of Medical Physiology; Harrison's Principles of Internal Medicine, 22e; Rheumatology (Hochberg), 2022. Classification and effects per KD Tripathi Essentials of Medical Pharmacology, 8th edition.

This is a shared conversation. Sign in to Orris to start your own chat.